One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis  (4/28/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
Source: Streetwise Reports  (4/28/25)
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.

More >

Biotech Company Reports Promising Neurological Treatment in Clinical Study
Source: Streetwise Reports  (4/25/25)
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year. More >

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Source: Streetwise Reports  (4/24/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company. More >

Biotech Discovers Revolutionary Immunotherapy in Houston
Source: Jason Kolbert  (4/24/25)
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note. More >

Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Source: Dr. Douglas Loe  (4/14/25)
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential. More >

New Drug for Early AD Shown to be Efficacious, Safe
Source: Jason Kolbert  (4/9/25)
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report. More >

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert  (4/9/25)
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. More >

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju  (4/9/25)
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. More >

Share Price Appreciation of Biotech Due Over Next Six Months
Source: Dr. David Nierengarten  (4/8/25)
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. More >

New Therapy for AATD Could be Best in Class
Source: Patrick Trucchio  (4/8/25)
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Source: Streetwise Reports  (4/8/25)
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential. More >

Biotech Co. Has Promising AI-Accelerated Pipeline
Source: Alexander Rihane  (4/7/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. More >

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.
Source: Streetwise Reports  (4/7/25)
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest. More >

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe
Source: Streetwise Reports  (4/7/25)
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said. More >

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results
Source: Streetwise Reports  (4/4/25)
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential. More >

Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports  (4/3/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication. More >

Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe  (4/3/25)
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. More >

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Source: Jason Kolbert  (4/3/25)
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report. More >

New Jersey Pharma Co. Shares Positive Pediatric Study
Source: Dr. Ram Selvaraju  (4/2/25)
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note. More >

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
Source: Streetwise Reports  (4/1/25)
BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story. More >

GMP Production of Exosomes Slated for Later This Year
Source: Jason Kolbert  (3/31/25)
This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report. More >

Biotech Co. Advances AI-Generated Cancer Treatments
Source: Streetwise Reports  (3/28/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) receives the first synthesized batch of artificial intelligence-generated ATR inhibitor compounds developed in collaboration with Variational AI. Find out why the technology could revolutionize the way we treat cancer. More >

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases
Source: Streetwise Reports  (3/28/25)
Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough." More >

Chen Highlights His Premium Silver, Gold Opportunities for Q2
Source: Streetwise Reports  (3/25/25)
Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter. More >